Keywords: pharmacopeia, cxcr2, drug, shows, efficacy, ph, innovator
Pharmacopeia's CXCR2 drug shows efficacy in Ph I
Article | 20 March 2006
Pharmacopeia, a US innovator in the discovery and development of novel small-molecule therapeutics, says that a CXCR2 antagonist, developed in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
